Results 1 to 10 of about 4,843 (156)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE) [PDF]

Frontiers in Cardiovascular Medicine, 2022
BackgroundLow-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and ...
Isabella Sudano, Francois Mach, Tiziano Moccetti, Thilo Burkard, Christian Fahe, Alain Delabays, Hans Rickli, Pierre-Frédéric Keller, Jörn Dopheide, Jörn Dopheide, Sereina Bodenmann, Tom Fiolka, Georg Ehret, David Spirk, David Spirk   +14 more
doaj   +3 more sources

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S] [PDF]

Journal of Lipid Research, 2014
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development.
Susan Kühnast, José W.A. van der Hoorn, Elsbet J. Pieterman, Anita M. van den Hoek, William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J. Wouter Jukema, Hans M.G. Princen   +10 more
doaj   +2 more sources

Effect of alirocumab on cataracts in patients with acute coronary syndromes [PDF]

BMC Ophthalmology, 2023
Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone.
Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, J. Wouter Jukema, Garen Manvelian, Yann Poulouin, Robert Pordy, Michel Scemama, Michael Szarek, Ph. Gabriel Steg, ODYSSEY OUTCOMES Investigators   +10 more
doaj   +2 more sources

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Journal of the American Heart Association, 2016
Background The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low‐density lipoprotein‐cholesterol (LDL‐C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 
Erik Stroes, Henry N Ginsberg, Jennifer G Robinson   +2 more
exaly   +2 more sources

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol [PDF]

Cardiovascular Diabetology, 2020
Background Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk.
Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller-Wieland, Bertrand Cariou, Kausik K. Ray, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Marc Israel, Rita Samuel, Stefano Del Prato   +10 more
doaj   +3 more sources

Observational, Multicenter study on long-term Effectiveness and tolerability of aliROcumab (OMERO): an Italian real-life experience [PDF]

International Journal of Cardiology. Cardiovascular Risk and Prevention
Background: The OMERO study (Observational Multicenter study on Effectiveness and tolerability of aliROcumab in real-world) aimed to evaluate the long-term effectiveness, safety and adherence of alirocumab in a cohort of Italian patients with elevated ...
Alberico L. Catapano, Aldo Pietro Maggioni, Francesco Rossi, Eleonora Consolo, Lucia Notarianni, Giancarlo Agnelli   +5 more
doaj   +2 more sources

The Impact of Single-Dose Alirocumab on Efficacy and Safety After Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Single-Center Retrospective Real-World Study [PDF]

Reviews in Cardiovascular Medicine
Background: Residual inflammation and persistent lipid abnormalities substantially increase the risk of adverse clinical outcomes in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (
Pei Wang, Haixia Wang, Dongdong Yan, Zheng Zhang   +3 more
doaj   +2 more sources

Alirocumab and cardiovascular outcomes after acute coronary syndrome [PDF]

, 2018
BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9 ...
Steg, PG, Diaz, R, Mahaffey, KW, Hanotin, C, Schwartz, GG, Bittner, VA, Goodman, SG, Bhatt, DL, Coverdale, Steven, Edelberg, JM, Harrington, RA, Jukema, JW, Lecorps, G, et al., Szarek, M   +14 more
core   +6 more sources

The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis [PDF]

Frontiers in Pharmacology
ObjectiveIn December 2021, evolocumab and alirocumab were included in the National Reimbursement Drug List Negotiation (NRDLN), with implementation commencing in January 2022.
Wan Tang, Wan Tang, Wei Li, Wei Li, Anqi Zhang, Huanhuan Wu, Huanhuan Wu, Wei Lu, Wei Lu, Yan Fan, Yan Fan   +10 more
doaj   +2 more sources

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis [PDF]

Scientific Reports
Recent case reports linked use of the lipid-lowering class of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to severe hypersensitivity reactions.
Foteini Dermiki-Gkana, Christopher A. Gravel, Christos Kontogiorgis, Antonios Douros   +3 more
doaj   +2 more sources